EQ-VAS scores from our patients (mean ± SD, 72.7 ± 14.5) were significantly higher than those reported in a European SCA3 cohort with mixed ataxia severities (mean ± SD, 59.1 ± 21.6, difference p = 0.001) but lower than scores from preclinical SCA3 mutation carriers (median 85, IQR 78-91) [4, 7]. This evidence concerns the gene ATXN3 and Ataxia.